Cargando…

Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance

SIMPLE SUMMARY: PARP inhibitors (PARPi; olaparib) are presently in clinical trials for advanced prostate cancer (PC). Resistance mechanisms are not fully understood in PC compared to ovarian and breast cancers. Our study aimed to identify new molecular mechanisms that affect acquired olaparib-resist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cahuzac, Maxime, Péant, Benjamin, Mes-Masson, Anne-Marie, Saad, Fred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405809/ https://www.ncbi.nlm.nih.gov/pubmed/36010871 http://dx.doi.org/10.3390/cancers14163877

Ejemplares similares

Pre-activation of autophagy impacts response to olaparib in prostate cancer cells
por: Cahuzac, Maxime, et al.
Publicado: (2022)

IKKε Inhibitor Amlexanox Promotes Olaparib Sensitivity through the C/EBP-β-Mediated Transcription of Rad51 in Castrate-Resistant Prostate Cancer
por: Gilbert, Sophie, et al.
Publicado: (2022)

Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality
por: Clairefond, Sylvie, et al.
Publicado: (2021)

PUMA and NOXA Expression in Tumor-Associated Benign Prostatic Epithelial Cells Are Predictive of Prostate Cancer Biochemical Recurrence
por: Clairefond, Sylvie, et al.
Publicado: (2020)

Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability
por: Gilbert, Sophie, et al.
Publicado: (2022)

Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer
por: Lounis, Mohamed Amine, et al.
Publicado: (2020)

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
por: Amuzu, Setor, et al.
Publicado: (2021)

Elevated Expression of Glycerol-3-Phosphate Phosphatase as a Biomarker of Poor Prognosis and Aggressive Prostate Cancer
por: Lounis, Mohamed Amine, et al.
Publicado: (2021)

Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay
por: Labouba, Ingrid, et al.
Publicado: (2015)

IκB-Kinase-epsilon (IKKε) over-expression promotes the growth of prostate cancer through the C/EBP-β dependent activation of IL-6 gene expression
por: Péant, Benjamin, et al.
Publicado: (2016)

Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer
por: Gannon, Philippe O., et al.
Publicado: (2010)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems
por: Patra, Bishnubrata, et al.
Publicado: (2020)

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
por: Fedier, André, et al.
Publicado: (2022)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer
por: Boudhraa, Zied, et al.
Publicado: (2021)

A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis
por: Communal, Laudine, et al.
Publicado: (2021)

High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality
por: Dariane, Charles, et al.
Publicado: (2022)

Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer
por: Stanzione, Marcello, et al.
Publicado: (2022)

Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors
por: Diallo, J-S, et al.
Publicado: (2008)

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib
por: Gong, Lifeng, et al.
Publicado: (2022)

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer()
por: Lombard, Alan P, et al.
Publicado: (2019)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
por: Su, Dan, et al.
Publicado: (2021)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
por: Sekine, Mana, et al.
Publicado: (2023)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
por: De Felice, Francesca, et al.
Publicado: (2017)

Ebp1 expression in benign and malignant prostate
por: Gannon, Philippe O, et al.
Publicado: (2008)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

Influence of pH on the Cytotoxic Activity of Inositol Hexakisphosphate (IP6) in Prostate Cancer
por: Betton, Blandine, et al.
Publicado: (2011)

Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines
por: Donix, Lukas, et al.
Publicado: (2022)

Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma
por: Hu, Dianxing, et al.
Publicado: (2022)

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
por: Vaidyanathan, Aparajitha, et al.
Publicado: (2016)

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer
por: Carr, T. Hedley, et al.
Publicado: (2021)

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance
por: Horak, Peter, et al.
Publicado: (2019)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report
por: Yuan, Fang, et al.
Publicado: (2022)

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
por: Matsubara, Nobuaki, et al.
Publicado: (2023)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

Microdissected Tissue vs. Tissue Slices—A Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip
por: Dorrigiv, Dina, et al.
Publicado: (2021)

Olaparib is effective in combination with, and as maintenance therapy after, first‐line endocrine therapy in prostate cancer cells
por: Feiersinger, Gertrud E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ilf4po2os24fqk3d46tuas5pia